The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.

Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, Drewett LM, Lucey R, Fulton A, Roberts AN, Worley JR, Chhabra A, Qian W, Vallier AL, Hardy RM, Chan S, Hickish T, Tripathi D, Venkitaraman R, Persic M, Aslam S, Glassman D, Raj S, Borley A, Braybrooke JP, Sutherland S, Staples E, Scott LC, Davies M, Palmer CA, Moody M, Churn MJ, Newby JC, Mukesh MB, Chakrabarti A, Roylance RR, Schouten PC, Levitt NC, McAdam K, Armstrong AC, Copson ER, McMurtry E, Tischkowitz M, Provenzano E, Earl HM

Open source

DOI: 10.1038/s41586-024-07384-2
Published: 2024 May
Container: Nature
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41586-024-07384-2,
  title = {The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.},
  author = {Abraham JE and Pinilla K and Dayimu A and Grybowicz L and Demiris N and Harvey C and Drewett LM and Lucey R and Fulton A and Roberts AN and Worley JR and Chhabra A and Qian W and Vallier AL and Hardy RM and Chan S and Hickish T and Tripathi D and Venkitaraman R and Persic M and Aslam S and Glassman D and Raj S and Borley A and Braybrooke JP and Sutherland S and Staples E and Scott LC and Davies M and Palmer CA and Moody M and Churn MJ and Newby JC and Mukesh MB and Chakrabarti A and Roylance RR and Schouten PC and Levitt NC and McAdam K and Armstrong AC and Copson ER and McMurtry E and Tischkowitz M and Provenzano E and Earl HM},
  year = {2024},
  journal = {Nature},
  doi = {10.1038/s41586-024-07384-2},
  url = {https://doi.org/10.1038/s41586-024-07384-2}
}

RIS

TY  - JOUR
TI  - The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
AU  - Abraham JE
AU  - Pinilla K
AU  - Dayimu A
AU  - Grybowicz L
AU  - Demiris N
AU  - Harvey C
AU  - Drewett LM
AU  - Lucey R
AU  - Fulton A
AU  - Roberts AN
AU  - Worley JR
AU  - Chhabra A
AU  - Qian W
AU  - Vallier AL
AU  - Hardy RM
AU  - Chan S
AU  - Hickish T
AU  - Tripathi D
AU  - Venkitaraman R
AU  - Persic M
AU  - Aslam S
AU  - Glassman D
AU  - Raj S
AU  - Borley A
AU  - Braybrooke JP
AU  - Sutherland S
AU  - Staples E
AU  - Scott LC
AU  - Davies M
AU  - Palmer CA
AU  - Moody M
AU  - Churn MJ
AU  - Newby JC
AU  - Mukesh MB
AU  - Chakrabarti A
AU  - Roylance RR
AU  - Schouten PC
AU  - Levitt NC
AU  - McAdam K
AU  - Armstrong AC
AU  - Copson ER
AU  - McMurtry E
AU  - Tischkowitz M
AU  - Provenzano E
AU  - Earl HM
PY  - 2024
JO  - Nature
DO  - 10.1038/s41586-024-07384-2
UR  - https://doi.org/10.1038/s41586-024-07384-2
ER  -

APA

JE, A., K, P., A, D., L, G., N, D., C, H., LM, D., R, L., A, F., AN, R., JR, W., A, C., W, Q., AL, V., RM, H., S, C., T, H., D, T., R, V., M, P., S, A., D, G., S, R., A, B., JP, B., S, S., E, S., LC, S., M, D., CA, P., M, M., MJ, C., JC, N., MB, M., A, C., RR, R., PC, S., NC, L., K, M., AC, A., ER, C., E, M., M, T., E, P., & HM, E. (2024). The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.. Nature. https://doi.org/10.1038/s41586-024-07384-2

Source records

pubmed · retrieved 2026-09-27T12:15:15.249Z